Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis [4]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 118-119

  Sungkanuparph, Somnuek ^a   Vibhagool, Asda ^a   Mootsikapun, Piroon ^b   Chetchotisakd, Ploenchan ^b   Tansuphaswaswadikul, Somsit ^c   Bowonwatanuwong, Chureeratana ^d   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Bamrasnaradura Hospital   (Thailand)

^d CHONBURI HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNGAL MENINGITIS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INSOMNIA; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VIRUS LOAD;

EID: 0038372679     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00019     Document Type: Letter

References (10)

1. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
2. British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2:276-313.
3. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-253.
4. Plosker GL, Perry CM, Goa KL. Efavirenz: a pharmacoeconomic review of its use in HIV infection. Pharmacoeconomics. 2001;19:421-436.
5. Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/ml and opportunistic diseases: the EfaVIP Study (Efavirenz in very immunosuppressed patients). AIDS. 2002;16:1554-1556.
6. Kebba A, Atwine D, Mwebaze R, et al. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses. 2002; 18:1181-1187.
7. Hartmann M, Rump A, Brust J, et al. Evaluation of an efavirenzcontaining regimen: an open-label, multicenter study. HIV Clin Trials. 2001;2:421-428.
8. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22:930-933.
9. Moyle GJ. Considerations in the choice of protease inhibitorsparing regimens in initial therapy for HIV-1 infection. Curr Opin Infect Dis. 2000;13:19-25.
10. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.